[Molecular imaging of tumor hypoxia]

Area of Science:

• Oncology
• Radiology
• Molecular Imaging

Background:

• Positron emission tomography (TEP) using (18)F-fluorodesoxyglucose ([(18)F]-FDG) is currently the standard for cancer assessment.
• Emerging molecular markers and imaging techniques are poised to revolutionize cancer care.
• Tumor hypoxia is a critical factor linked to treatment resistance in many cancers.

Purpose of the Study:

• To review the role of molecular imaging in assessing tumor hypoxia.
• To highlight the potential of (18)F-fluoromisonidazole TEP ([(18)F]-MISO TEP) in cancer management.
• To examine the application of hypoxia imaging in head and neck tumors and glioblastomas.

Main Methods:

• Review of existing literature on molecular imaging of tumor hypoxia.
• Focus on the utility of (18)F-fluoromisonidazole TEP for mapping hypoxic regions.
• Analysis of the impact of hypoxia imaging on prognosis and treatment planning.

Main Results:

• [(18)F]-MISO TEP provides valuable information on tumor hypoxia, aiding in prognosis and radiotherapy delineation.
• Head and neck tumors show significant correlation between hypoxia and therapeutic outcomes.
• Hypoxia imaging may be crucial for evaluating targeted therapies and developing new treatment strategies.

Conclusions:

• Molecular imaging of tumor hypoxia, particularly using [(18)F]-MISO TEP, offers significant potential to improve cancer patient care.
• Further research is needed to confirm the benefits of [(18)F]-MISO TEP in brain tumors.
• Addressing tumor hypoxia is essential for enhancing therapeutic results in challenging cancers like glioblastomas.